Free

This is a free video, please log in to watch it and claim CPD.

Watch Now

To see Member's videos, become a member today!

Join Us

Back to Video List

DOPAVIEW (fluorodopa (18F)) for PET imaging in oncology and neurology 25 Nov 2020

In this webinar, professors in nuclear medicine, David Taïeb (La Timone University Hospital, Marseille, France) and Jacques Darcourt (Centre Antoine Lacassagne, Nice, France) presented their experience with DOPAVIEW (fluorodopa (18F)) for diagnostic imaging procedures within neurology and oncology applications. 


Chaired by: 

Professor Jamshed Bomanji (University College London Hospital, UK) 

Dr Nicola Mulholland (King’s College Hospital London, UK)


Speakers:

Professor David Taïeb (Professor in Nuclear Medicine, La Timone University Hospital, Marseille, France)

Professor Jacques Darcourt (Professor of Biophysics and Nuclear Medicine, Centre Antoine Lacassagne, Nice, France)


DOPAVIEW 222 MBq/mL solution for injection is indicated for use with positron emission tomography (PET) in adults and paediatric population. This meeting was organised and funded by Advanced Accelerator Applications, a Novartis company. Advanced Accelerator Applications products are discussed. Prescribing information can be found here.


AAA-Fl18F-UK-0015 | March 2021


4 CPD credits.

Watch the video and complete the online self-reflection form. Go to "My events" to download your certificate. You must login to watch the video and receive CPD.


Biographies of the Chairs:

Professor Jamshed Bomanji, Clinical Lead and Head of Clinical Department, Institute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust. 

image.png

Professor Jamshed Bomanji graduated in 1980 from Punjab University. After moving to the UK in 1984, he completed his postgraduate education at St Bartholomew’s Hospital acquiring his master’s degree in 1984 and PhD in nuclear medicine in 1987. In 1990, he was appointed Consultant in Nuclear Medicine at St Bartholomew’s Hospital. Professor Bomanji moved to The Middlesex Hospital in 1993 (part of University College London Hospitals NHS Foundation Trust) and for the past 26 years he has served as Consultant Physician within this trust. Since 2009, he has been the Clinical Lead and Head of Clinical Department at the Institute of Nuclear Medicine (INM). Under his leadership and guidance, the INM has become the largest single-site department in the UK and attracts international attention from around the world. It has established a world-renowned reputation as an international centre of excellence and attracts grants exceeding £7m+. His main research interests are in using unsealed radioactive agents for benign and malignant diseases particularly in oncology, nephrology/urology, infectious disease, cardiology and neuroimaging. To this end, over the past 25 years, he has developed/facilitated cross-speciality, multi-institutional translational research programmes.

Professor Bomanji has contributed and published more than 231 articles, 6 books and has worked as Editor of Nuclear Medicine Communications and Assistant/Advisory Editor on various other journals in the field of nuclear medicine. He continues to develop academic and clinical training for the next generation of students, junior and postgraduate staff and is considered one of the major leads and pioneers in his field.

This meeting is organised and funded by Advanced Accelerator Applications, a Novartis company. Advanced Accelerator Applications products will be discussed at this meeting. AAA-Fl18F-UK-0004 | October 2020


Dr Nicola Mulholland, Consultant Physician in Nuclear Medicine, King's College Hospital NHS Foundation Trust.

image.png

Dr Nicola Mulholland trained in medicine at Universities of Cambridge and London, gaining a distinction in finals and an MSc in nuclear medicine. Following dual training as a consultant clinical radiologist and nuclear medicine physician, she was appointed at King’s College Hospital, London, in 2007 where she is now the departmental lead for nuclear medicine and positron emission tomography/computed tomography (PET/CT), which includes the first digital PET/CT in NHS England. She is Honorary Senior Lecturer in Imaging Sciences at King's College London, College Representative for the Royal College of Physicians and Educational Supervisor. Dr Mulholland has a wide clinical and research portfolio and has delivered many invited lectures both nationally and internationally on molecular medicine.

This meeting is organised and funded by Advanced Accelerator Applications, a Novartis company. Advanced Accelerator Applications products will be discussed at this meeting. AAA-Fl18F-UK-0004 | October 2020


Biographies of the speakers:

Professor David Taïeb, Professor in Nuclear Medicine, La Timone University Hospital, Marseille, France.

image.png

Professor David Taïeb is full professor of Nuclear Medicine at Aix Marseille University in France and is a member of the European Association of Nuclear Medicine (EANM) Oncology & Theranostics Committee. He holds numerous research grants and is co-editor of two textbooks dedicated to nuclear endocrinology. He has over 200 peer-reviewed publications.

A major focus of his clinical research in collaboration with the National Institutes of Health has been to assess the relationship between imaging phenotypes and genotypes in endocrine malignancies. He is also actively involved in radionuclide therapy with a major focus on endocrine neoplasms. Professor Taïeb is also affiliated with INSERM (French Institute of Health and Medical Research) with several ongoing basic research projects on castration-resistant prostate cancer and nanotheragnostics. More recently, he has coordinated the EANM Practice Guideline/Society of Nuclear Medicine and Molecular Imaging (SNMMI) Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma (PPGL).

https://publons.com/researcher/2071785/david-taieb/

This meeting is organised and funded by Advanced Accelerator Applications, a Novartis company. Advanced Accelerator Applications products will be discussed at this meeting. AAA-Fl18F-UK-0004 | October 2020


Professor Jacques Darcourt, Professor of Biophysics and Nuclear Medicine, Centre Antoine Lacassagne, Nice, France.

image.png

Professor Jacques Darcourt is currently Professor of Biophysics and Nuclear Medicine at the Université Côte d’Azur and also Head of the Nuclear Medicine Department at the Centre Antoine Lacassagne, Nice, France.

Professor Darcourt completed his medical training at the Université Côte d’Azur in 1979 and later in 1992 became Visiting Professor in Nuclear Medicine at the Harbor-UCLA Medical Center, Los Angeles, USA.

Professor Darcourt has held various titles including, Maître de Conférences-Praticien Hospitalier from 1989 to 1992 and has since then held the title of Professeur des Universités-Praticien Hospitalier (PU-PH). He was Chair of the European Association of Nuclear Medicine (EANM) Neuroimaging Committee from 2010 to 2012 and has also been a member of the European School of Multimodality Imaging and Therapy (ESMIT) working group level 3 since 2016 and member of the level 2 task force since 2019.

This meeting is organised and funded by Advanced Accelerator Applications, a Novartis company. Advanced Accelerator Applications products will be discussed at this meeting. AAA-Fl18F-UK-0004 | October 2020

Duration:84 mins